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After  decades  of extensive  experimental  and  clinical  research,  septic  shock  and  the  related  multiple  organ
dysfunction  still  remain  the  leading  cause  of  mortality  in  intensive  care  units  (ICUs)  worldwide.  Deﬁn-
ing sepsis  is  a difﬁcult  task,  but  what  is even  more  challenging  is differentiating  infection-induced  from
non-infection-induced  systemic  inﬂammatory  response-related  multiple  organ  dysfunction.  As  conven-
tional  signs  of  infection  are often  unreliable  in intensive  care,  biomarkers  are used,  of which  one of the
most  frequently  investigated  is  procalcitonin.  Early stabilisation  of  vital  functions  via adequate  support-
ive  therapy  and  antibiotic  treatment  has  resulted  in substantial  improvements  in outcome  over  the  last
decades.  However,  there  are  certain  patients  who  may  need  extra  help,  hence  modulation  of  the  immune
system  and  the  host’s  response  may  also  be an  important  therapeutic  approach  in  these  situations.  Poly-
clonal  intravenous  immunoglobulins  have  been  used  in critical  care  for  decades.  A relatively  new  potential
approach  could  be  attenuation  of  the overwhelming  cytokine  storm  by  speciﬁc  cytokine  adsorbents.  Both
interventions  have  been  applied  in daily practice  on a large  scale,  with  ﬁrm  pathophysiological  rationale
but  weak  evidence  supported  by clinical  trials.  The  purpose  of this  review  is to give an  overview  on the
pathophysiology  of sepsis  as  well  as  the  role  and  interpretation  of  biomarkers  and  their potential  use  in
assisting  adjunctive  therapies  in  sepsis  in  the  future.
lsevie©  2015  E
. Introduction
Diagnosing and treating severe bacterial infections and related
ultiple organ dysfunction in the intensive care unit (ICU) is one
f the biggest challenges in critical care medicine. As these patients
orrespond to a very heterogeneous population, varying in aeti-
logy and severity, universally applicable diagnostic criteria and
reatment protocols for sepsis are difﬁcult to deﬁne. Neverthe-
ess, sepsis has become a very important public health issue all
round the world for several reasons. The incidence of sepsis has
ncreased during the past decades, with mortality rates of 20–50%,
nd sepsis appears to be the single most important reason for
ospitalisation [1–3]. Therefore, improving outcome is of utmost
mportance for patients and healthcare providers alike. Unfortu-
ately, more than 30 years of extensive clinical research resulted
n mainly non-signiﬁcant results. According to a recent review of
2 prospective randomised trials with mortality being the pri-
ary endpoint, 55 ended up with non-signiﬁcant results, also
∗ Corresponding author.
E-mail address: zsbecze@t-online.hu (Z. Becze).
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.11.002
924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rightsr  B.V.  and  the  International  Society  of  Chemotherapy.  All  rights  reserved.
including several studies on adjuvant therapies [4,5]. Promising
positive results of single-centre studies were often contradicted
later by large multicentre trials [5]. Heterogeneity of the popula-
tions studied and diversity in clinical practice may  be just two  of
the most important limitations of multicentre trials leaving us dis-
appointed regarding several promising interventions. However, it
is important to acknowledge that ‘absence of evidence’ may  not
necessarily mean the ‘evidence of absence’.
Nevertheless, early detection of infection-induced critical illness
and the immediate start of resuscitation in parallel with ade-
quate antimicrobial therapy undoubtedly give the best possible
chance for survival and received strong recommendation by the
Surviving Sepsis Campaign guidelines [6]. However, whilst recog-
nising organ failure is relatively easy, diagnosing the underlying
infection remains a challenge. Owing to the non-speciﬁc proper-
ties of conventional signs of infection, such as body temperature
and white blood cell count, for decades biomarkers have been
searched for to aid diagnosis. One of the most studied biomark-
ers of the last decade is procalcitonin (PCT) [7]. Its role in assisting
antibiotic therapy has been studied extensively [8,9], but it may
also have a potential role in guiding adjunctive therapies in the
critically ill.
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Modulation of the immune system and the host’s response
as also been the focus of research interest. However, anti-
nﬂammatory therapies, such as anti-cytokines, anti-oxidants, etc.,
ave also been tested, but the results were disappointing [10,11].
evertheless, at least theoretically, attenuating the cytokine storm
n the early phase of critical illness may  provide some beneﬁts by
ounterbalancing the overwhelming pro-inﬂammatory response
12]. This concept provides the rationale of why the so-called ‘adju-
ant therapies’ may  have a role in these patients.
The purpose of the current review is to summarise the back-
round of why diagnosing sepsis, or to be more precise infection,
emains an everyday challenge for ICU physicians, and how PCT
ould be used to aid decision-making, including the commence-
ent of adjunctive therapies.
. Sepsis is not a ‘deﬁnitive’ disease
Deﬁning sepsis is not simple. The idea of ‘sepsis syndrome’ was
onceived in 1980, during the protocol writing of one of the ﬁrst
rospective randomised trials in sepsis, performed by Bone et al.,
nd was based on the inclusion criteria of that study [13,14]. The
lassical signs of ‘sepsis syndrome’, such as fever/hypothermia,
eukocytosis/leukopenia, tachycardia and hypotension, meant a
ery large and non-speciﬁc group of patients. A few years later a
onsensus conference was brought together and the ‘consensus
riteria’ for several deﬁnitions were published in 1992 [15]. This
oncept was also questioned and criticised [16]. In the most current
urviving Sepsis Campaign guidelines, a more robust and detailed
eﬁnition has been created, but fundamentally it is still following
he previous concept of the Bone criteria [6].
This confusion regarding the deﬁnition leaves us with obvious
ncertainties. It is difﬁcult to know for sure in which patients we
hould start antibiotics or commence adjuvant therapies, which
s still based on the physician’s ‘gut feeling’ rather than objective
arameters during our everyday practice.
. Pathophysiology: from localised insult to ‘cytokine
torm’
The immune system is a complex network and the immune
esponse to pathogens relies both on innate and adaptive compo-
ents. The ﬁrst line of defence against invaders consists of physical
arriers such as the skin [17,18] and the mucous membranes of the
espiratory [19], gastrointestinal [20] and genitourinary [21] tracts.
he second line of defence is the rapidly acting innate immune sys-
em (including the complement system, sentinel phagocytic cells
nd natural killer cells), which plays a modulatory role on the
daptive immune system [22]. The innate system acts by broad
ecognition of antigens, mainly by triggering pathogen-associated
olecular patterns (PAMPs) of lipopolysaccharide (LPS) elements
n the surfaces of invading pathogens.
When a local response escalates into a systemic immune
esponse, activation of several signalling pathways on different
eceptors will generate a ‘cytokine storm’ [23]. It was a very impor-
ant discovery that following trauma, burns, ischaemia/reperfusion
njury, pancreatitis, major surgery, etc., the same or similar
olecules are released mainly from the mitochondria. These are
alled ‘damage-associated molecular patterns’ (DAMPs). Therefore,
t has now become clear that following cellular injury, similar pro-
eins (DAMPs) will be released as during bacterial infection (PAMPs)
ecause the genetics, and hence the proteins released, are very
imilar in bacteria and in the mitochondria [24].
In most cases, the PAMP- and DAMP-induced pro- and anti-
nﬂammatory forces swing into action alongside with each other,
ut remain in balance and after a certain period of time theirmicrobial Agents 46 (2015) S13–S18
activity returns to baseline and the infection is resolved. How-
ever, in critically ill patients this balance is disturbed and either the
pro- or anti-inﬂammatory forces overwhelm each other and the
localised insult becomes systemic. As a result, vital organs, distant
from the site of the initial insult, become affected in an unpre-
dictable manner. If two  or more vital organs are affected it is termed
multiple system organ failure. The processed is brieﬂy summarised
in Fig. 1. Organ dysfunction mainly means a DAMP-based imbalance
between oxygen delivery (DO2) and consumption (VO2), resulting
in a persistent non-speciﬁc inﬂammatory response. This process
exhausts resources of defence against infection. Therefore, some
adjunctive interventions are targeted to attenuate the DAMP-based
overwhelming pro-inﬂammatory forces (i.e. cytokine adsorption),
whilst other approaches boost immunological defence against the
invading pathogens (i.e. immunoglobulins).
4. Diagnostic challenges
Recognising a ‘septic patient’ per se is based on two main pil-
lars. The ﬁrst is evaluation of vital organ functions and the degree
of organ dysfunction via objective clinical signs [19]. The second
is the attempt to verify the aetiology of critical illness, in other
words whether or not it is due to infection. However, answering
this question remains one of the most difﬁcult tasks in our daily
practice. There is not, and most probably will never be, one sin-
gle marker that is able to diagnose sepsis, mainly due to its very
colourful manifestation and the heterogeneity of patients.
4.1. Conventional markers of inﬂammation/infection
It has been shown and accepted that early initiation of adequate
antibiotic therapy is of utmost importance, with the chances of
survival reducing by the hour [25]. Therefore, diagnosing infec-
tion as early as possible has a pivotal role in efﬁcient patient
management. Traditionally, physicians use clinical signs, body
temperature, white blood cell count and microbiological data to
diagnose infection. However, clinical signs, which are the most
important evidence in recognising organ dysfunction, are non-
speciﬁc and non-sensitive markers of a bacterial infection. Fever
and leukocytosis also have very poor sensitivity and speciﬁcity,
being not much better than just ﬂipping a coin. Microbiology is
the gold standard for conﬁrming pathogens, but the results come
back late, at least 24–48 h after sampling. New molecular biology
techniques can shorten the detection time of microbes but these
cannot differentiate between colonisation and clinically relevant
infection [26–28]. This is why we need laboratory tests that are
sensitive and speciﬁc enough to indicate bacterial infection within
hours of its onset. These biologically active substances are called
biomarkers.
4.2. The role of biomarkers at the bedside
There are several useful biomarkers in clinical practice and
extensive research is still ongoing to ﬁnd better ones [1]. However,
no biomarker can answer all questions alone with 100% sensitivity
and speciﬁcity in severe sepsis and septic shock owing to the over-
lapping pathomechanism of PAMPs and DAMPs discussed in detail
above [29].
The two most commonly used markers in infection/sepsis diag-
nostics are PCT and C-reactive protein (CRP) [30]. Despite their
popularity, there are still many pros and cons, with no clear answers
regarding their usefulness and interpretation in guiding patient
management, including adjunctive therapies.
PCT is detectable in the serum within a few hours (2–4 h) after
the onset of bacterial infection. It reaches its peak within 24 h and
then starts to decline in the case of adequate treatment, with ca.
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Fig. 1. Pathogenesis of sepsis and multiple system organ failure due to different insults. PAMP, pathogen-associated molecular pattern; DAMP, damage-associated molecular
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0% daily drop according to its half-life [31]. In contrast, CRP has
 similar but delayed response, and under certain circumstances it
eaches its maximum value usually within 48 h. Furthermore, CRP
evels are generally elevated in most ICU patients, making interpre-
ation of CRP very difﬁcult [32]. The other major problem with CRP
n the ICU is its slow kinetics, in other words it lags way behind the
ctual events of the inﬂammatory process.
PCT differentiates bacterial infections from systemic inﬂam-
atory response of other aetiologies with higher sensitivity and
peciﬁcity compared with CRP [33,34]. Discussing the available
vidence on PCT–CRP comparison is beyond the aim of this
anuscript, hence we will mainly focus on PCT in the coming
aragraphs. There is considerable evidence that a PCT-supported
olicy in antibiotic treatment has several beneﬁcial effects, such as
educed antibiotic prescription and exposure in lower respiratory
ract infections, with similar clinical outcome and survival [35], and
t may  also shorten the duration of antibiotic treatment in the ICU
36].
. Interpreting procalcitonin
As sepsis is often regarded as a ‘deﬁnitive’ disease, most physi-
ians wish for a certain absolute value of biomarkers to diagnose
epsis/infection. However, based on the previously discussed path-
mechanism (PAMP/DAMP/both), it should be acknowledged that
epsis is not a deﬁnitive disease, therefore it is impossible to have
ne single cut-off value for all conditions.
.1. Sepsis is different in surgical and medical patientsPCT levels were found to be several times higher in surgical com-
ared with medical patients with the same gravity of septic shock
37]. This indicates that the degree of the inﬂammatory response is
ifferent depending on aetiology [38–41].olase; HMGB-1, high-mobility group box 1; HSP, heat shock protein; IL, interleukin;
telet-activating factor; BBB, blood–brain barrier; ARDS, adult respiratory distress
Unspeciﬁc PCT elevations can also be found in the absence of
bacterial infection [42,43]. Mono induction of PCT due to DAMP-
based surgical tissue injury is reﬂected in elevated PCT values after
surgery, with a peak on the ﬁrst postoperative day followed by a
gradual decrease thereafter [44]. Theoretically, in surgical patients
with infectious complications, DAMP and PAMP pathomechanisms
take place at the same time resulting in a synergistic effect on the
inﬂammatory response and a re-induction of PCT production with
increasing levels. In contrast, in medical patients it is primarily
the activation of PAMPs, resulting in a less extensive inﬂamma-
tory response, hence lower PCT levels. For example, in a study by
Clec’h et al., the median (interquartile range) PCT values in sys-
temic inﬂammatory response syndrome in medical versus surgical
patients were 0.3 (0.1–1.0) ng/mL vs. 5.7 (2.7–8.3) ng/mL, and in
septic shock were 8.4 (3.6–76.0) ng/mL vs. 34.0 (7.1–76.0) ng/mL,
respectively [37].
Furthermore, sepsis changes its ‘face’ with time. Charles et al.
found different degrees of inﬂammatory response despite a similar
clinical picture (i.e. organ dysfunction) in patients during their ﬁrst
compared with their second and third septic hit [45]. They investi-
gated patients with primary and secondary bloodstream infections
and found that the same gravity of infection indicated by the clinical
picture was  accompanied by a several times lower PCT maximum
concentration in patients with the second event of infection com-
pared with those with a primary event. This indicates that lower
levels of PCT should be taken just as seriously in the case of a later
onset of infection as higher values during the ﬁrst hit. These data
have been further supported by recent reports [46,47].
5.2. Kinetics over absolute valuesDespite the above differences in the absolute values in differ-
ent conditions, the kinetics may  show a similar pattern and may
also be more useful. Tsangaris et al. studied patients who  were
in the ICU for more than 10 days, who  were free of infection and
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ho presented with a new onset of fever [48]. PCT showed a mini-
um  2-fold increase in patients with proven infection from the day
efore to the day of fever onset. However, in patients without infec-
ion, PCT remained constantly low compared with previous days.
hey concluded that PCT values on the day of fever onset must be
ompared with values from the previous day to diagnose infection.
urthermore, in the case of a ‘normal’ clearance and the absence
f re-induction, PCT values on the third day after the fever onset
eturning to the normal range were associated with better survival
48]. These are in accord with a recent pilot study by Öveges et al.
49]. In patients in the ICU, the change of PCT from the day before
o the day when infection was suspected showed signiﬁcant differ-
nces in cases when infection was proven compared with those in
hom infection could not be proven. Although PCT values on the
revious day were similar in both groups, there was a signiﬁcant
ncrease in patients with infection, whilst there was no change in
he non-infection group [49]. These results indicate that PCT change
i.e. kinetics) may  be more useful than absolute values in diagnosing
nfection.
PCT kinetics may  also be very useful in stopping antibiotic ther-
py according the patient’s individual response. As indicated in the
RORATA trial, a >80% drop over a few days compared with the
eak PCT value can be an important signal to discontinue antibiotic
herapy, hence reducing antibiotic exposure signiﬁcantly without
ffecting outcome [36]. Tailoring the length of antibiotic therapy
ccording to biomarker levels is also recommended in the recent
urviving Sepsis Campaign guidelines [6]. These results suggest
hat PCT kinetics-based therapy may  be superior to pre-set abso-
ute values. Nevertheless, further studies are needed to reinforce
he ﬁndings of the PRORATA trial.
. When to commence adjuvant therapies?
In the world of evidence-based medicine, adjunctive therapies
ave a very difﬁcult task to prove themselves. Mainly single-centre
r small studies show therapeutic beneﬁt on outcome, and these
ositive results are often contradicted by large multicentre tri-
ls. Nevertheless, from a pathophysiological point of view, most of
hese therapeutic modalities have a ﬁrm pathophysiological ratio-
ale. Despite the lack of clear evidence, adjuvant therapies are still
requently used all over the world in the everyday practice, but
iscussing them all would be well beyond the scope of this article.The purpose of the current review is to show how a PCT-assisted
pproach can help to indicate the commencement of adjunc-
ive therapies. We  have chosen two alternatives: IgM-enriched
mmunoglobulins (Pentaglobin®; Biotest Pharma GmbH, Dreieich,Time
 sepsis. ATB, antibiotics; PCT, procalcitonin. See text for explanation.
Germany), which have long been used in our everyday practice; and
a new possibility for cytokine adsorption (CytoSorbTM; CytoSor-
bents Europe GmbH, Berlin, Germany).
Several properties of IgM-enriched intravenous immunoglob-
ulins make this preparation suitable for immunomodulatory
treatment in septic patients: it is able to facilitate the removal of
apoptotic cells [50] and protect from endotoxin-related endothe-
lial damage in parallel with successful antibiotic treatment [51].
Although there are no large prospective randomised trials to sup-
port their use on an evidence-based level, owing to the ﬁrm
pathophysiological rationale it has been used for decades. However,
the treatment is costly and there is frank evidence that patients can
survive in large numbers simply getting supportive and appropriate
antibiotic therapy. Nevertheless, there may  be patients that beneﬁt
from IgM-enriched immunoglobulin treatments, but it is difﬁcult
to deﬁne when and in whom it should be commenced [52].
CystoSorbTM contains biocompatible, porous polymer
polystyrene beads in a cartridge of ca. 300 mL  that is able to
adsorb a broad spectrum of cytokines in the 10–70 kDa range, both
including pro- and anti-inﬂammatory cytokines [53–55].
As cytokine overproduction is a common feature in many life-
threatening conditions in critically ill patients, such as sepsis, adult
respiratory distress syndrome, major surgery in high-risk patients,
trauma, viral infections, thermal injury, liver failure, acute pan-
creatitis, etc., the rationale for the use of a cytokine absorber
theoretically should not be limited for sepsis only but for any
critically ill conditions accompanied by a cytokine storm, hence
an imbalance between the pro- and anti-inﬂammatory forces.
Although at present there are only animal studies [56,57] and case
reports [58–62], several prospective randomised trials are taking
place worldwide [59].
Despite these positive results, the question remains why and
when should we  commence these therapies, if we do it at all,
and which patients would beneﬁt the most? By and large it fol-
lows some rationale that adjunctive therapies are indicated in the
case of: (i) profound septic shock, indicated by high vasopressor
requirement and multiple organ failure with at least two organs
involved; (ii) no improvement within a few hours after the com-
mencement of resuscitation and antimicrobial therapy; and (iii)
when PCT values remain unchanged or increase in addition to not
improving clinical conditions. This concept is summarised in Fig. 2.
There is some evidence that PCT values reﬂect adequate or inad-
equate treatment within hours, or at least within the ﬁrst 24 h,
and kinetics may  indicate appropriate or inappropriate treatment
[63]. However, this assumption will have to be tested in future
clinical trials. All we can say at the moment is that a multimodal,
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ndividualised approach may  help us to tailor these therapies
etter. The ‘multimodal’ approach means that several clinical
nd biochemical parameters are taken into account simulta-
eously, whilst ‘individualised’ refers to the interpretation of
hanges/kinetics of certain parameters such as PCT, rather than
aking only ‘ﬁxed’ absolute values into account.
. Conclusion
Understanding the aetiology and the underlying pathology in
epsis and critical illness is essential to enable us to evaluate clinical
igns and biomarkers in the right context. Several important issues
hould be taken into account during this evaluation, including
he immunological background of the host response for different
nsults, summarised in the DAMP/PAMP concept. This also explains
hy biomarker levels may  have different meanings due to differ-
nt aetiology and why their kinetics, in other words their change
ver time, may  provide more appropriate information than the
bsolute values. Designing future clinical trials based on recruit-
ng patients with different aetiologies and then treated according
o this concept may  overcome the shortcomings of trials in the past
nd provide results on a more homogeneous group of patients and
ith more conclusive results. This may  take us to a completely dif-
erent strategy in our therapeutic management, leading us towards
ultimodal, individualised, goal-directed infection management in
eptic patients.
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